U.S., Sept. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07829926) titled 'Lenvatinib Plus Tislelizumab With or Without Gefitinib for Advanced Liver Cancer' on Sept. 11.
Brief Summary: This study is for people with unresectable or advanced hepatocellular carcinoma who have not received previous systemic treatment for liver cancer.
The study will compare lenvatinib plus tislelizumab with or without gefitinib. Participants will be randomly assigned to receive either lenvatinib, tislelizumab, and gefitinib, or lenvatinib and tislelizumab. The study is open-label, so participants and study doctors will know the treatment group.
The main outcomes are progression-free survival and the number of participants w...